Log inSign Up
Research, regulation analysis, field reports, and product updates from the team building the reference layer for clinical AI.
An independent FDA regulatory firm reviewed our consumer and provider reports. Here is what they concluded, and why the product was built to land there.
Nata Savaścienka BloodGPT
As frontier models get more capable, they get harder to understand. In clinical work that opacity is not an inconvenience, it is the failure. A note from our CTO.
A Stanford-Harvard report names six unsolved problems in clinical AI. Better models won't close them. Better architecture will. Here's the mapping."
BloodGPT CEO Jonathan Kron on what he asked for at the European Commission focus group on clinical AI regulation, and why founders are leaving Europe.
The real danger of using AI for medical questions isn't what it tells you. It's what it leaves out. A new Stanford-Harvard study just proved it.
We scored 100% on Stanford's test for AI Medical Agents, the first perfect result on this clinical AI benchmark. Here is how we did it and what it means.
BloodGPT co-founder Nata Savaścienka spoke on a reimbursement strategies panel at LSX World Congress Europe in Lisbon, March 2026.
Five trends reshaping how health platforms deliver blood test results: AI prevention, contactless biomarkers, and actionable insights. Data from McKinsey, Gallup, and more.
FDA's January 2026 guidance cleared the path for AI. OpenAI and Anthropic (and later Amazon) launched enterprise healthcare products the same week. The window is open.
OpenAI’s ChatGPT Health shows where healthcare AI is heading: connected medical records, privacy controlsб and enterprise-grade foundations. Here’s what it means for BloodGPT.
Independent journalists, clinicians, and partners cover our work alongside us. Interviews, opinion pieces, and product coverage across healthcare and tech publications.